Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07428889 · ClinicalTrials.gov registry record · NA

Nicotinamide Adenine Dinucleotide Responses to a Nutritional Supplement

A NA study of Healthy Adult, sponsored by Shaklee Corporation.

Recruiting
Registry status
NA
Development phase
34
Enrollment target
1
Study location

NCT07428889: Recruiting NA study of Healthy Adult, sponsored by Shaklee Corporation.

NCT07428889 is a NA study of Healthy Adult that is actively recruiting participants, run by Shaklee Corporation. The registered enrollment target is 34 participants, below the 70-participant average among 8 other Healthy Adult trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07428889, a NA study of Healthy Adult, is actively recruiting participants, sponsored by Shaklee Corporation.

RECRUITING
Registry status
NA
Development phase
34 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to evaluate nicotinamide adenine dinucleotide (NAD+) in response to a proprietary nutritional supplement in generally healthy adults, compared to placebo.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Placebo Supplement
  • DIETARY_SUPPLEMENT Proprietary Nutritional Supplement

Study Locations (1)

Illinois

  • Biofortis Clinical Research - Addison

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2026-02
Est. Completion 2026-06
Phase NA
Shaklee Corporation

3 total trials

What NCT07428889 shows while recruiting

NCT07428889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 70-participant average among 8 other Healthy Adult trials with a reported enrollment target (51% lower).

The record links to 1 condition, with Healthy Adult appearing as the primary indexed condition, and to 2 interventions - of which Placebo Supplement is the first listed.

NCT07428889 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT07428889 about?

NCT07428889 is a clinical study titled "Nicotinamide Adenine Dinucleotide Responses to a Nutritional Supplement". The objective of this study is to evaluate nicotinamide adenine dinucleotide (NAD+) in response to a proprietary nutritional supplement in generally healthy adults, compared to placebo.

What is the current status of trial NCT07428889?

This trial is currently recruiting. It is a NA study. The enrollment target is 34 participants. The study started on 2026-02. Estimated completion is 2026-06.

What conditions does trial NCT07428889 study?

This clinical trial studies the following conditions: Healthy Adult.

What interventions are being tested in trial NCT07428889?

The interventions under investigation include: Placebo Supplement (DIETARY_SUPPLEMENT), Proprietary Nutritional Supplement (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT07428889?

This trial is sponsored by Shaklee Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07428889 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Adult

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07428889's enrollment target sits among peer trials

34 5th of 8 higher than 4 of 8 other Healthy Adult trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Adult trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT07428889, the US trial registry maintained by the National Library of Medicine. NCT07428889 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.